Repository logo
 
Publication

Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021

2023-11Journal article Open access
Simple item page
dc.contributor.authorRose, Angela M.C.
dc.contributor.authorNicolay, Nathalie
dc.contributor.authorSandonis Martín, Virginia
dc.contributor.authorMazagatos, Clara
dc.contributor.authorPetrović, Goranka
dc.contributor.authorNiessen, F Annabel
dc.contributor.authorMachado, Ausenda
dc.contributor.authorLaunay, Odile
dc.contributor.authorDenayer, Sarah
dc.contributor.authorSeyler, Lucie
dc.contributor.authorBaruch, Joaquin
dc.contributor.authorBurgui, Cristina
dc.contributor.authorLoghin, Isabela I.
dc.contributor.authorDomegan, Lisa
dc.contributor.authorVaikutytė, Roberta
dc.contributor.authorHusa, Petr
dc.contributor.authorPanagiotakopoulos, George
dc.contributor.authorAouali, Nassera
dc.contributor.authorDürrwald, Ralf
dc.contributor.authorHoward, Jennifer
dc.contributor.authorPozo, Francisco
dc.contributor.authorSastre-Palou, Bartolomé
dc.contributor.authorNonković, Diana
dc.contributor.authorKnol, Mirjam J.
dc.contributor.authorKislaya, Irina
dc.contributor.authorLuong Nguyen, Liem binh
dc.contributor.authorBossuyt, Nathalie
dc.contributor.authorDemuyser, Thomas
dc.contributor.authorDžiugytė, Aušra
dc.contributor.authorMartínez-Baz, Iván
dc.contributor.authorPopescu, Corneliu
dc.contributor.authorDuffy, Róisín
dc.contributor.authorKuliešė, Monika
dc.contributor.authorSoučková, Lenka
dc.contributor.authorMichelaki, Stella
dc.contributor.authorSimon, Marc
dc.contributor.authorReiche, Janine
dc.contributor.authorOtero-Barrós, María Teresa
dc.contributor.authorLovrić Makarić, Zvjezdana
dc.contributor.authorBruijning-Verhagen, Patricia C.J.L.
dc.contributor.authorGómez, Verónica
dc.contributor.authorLesieur, Zineb
dc.contributor.authorBarbezange, Cyril
dc.contributor.authorVan Nedervelde, Els
dc.contributor.authorBorg, Maria-Louise
dc.contributor.authorCastilla, Jesús
dc.contributor.authorLazar, Mihaela
dc.contributor.authorO’Donnell, Joan
dc.contributor.authorJonikaitė, Indrė
dc.contributor.authorDemlová, Regina
dc.contributor.authorAmerali, Marina
dc.contributor.authorWirtz, Gil
dc.contributor.authorTolksdorf, Kristin
dc.contributor.authorValenciano, Marta
dc.contributor.authorBacci, Sabrina
dc.contributor.authorKissling, Esther
dc.contributor.authorI-MOVE-COVID-19 Hospital Study Team
dc.contributor.authorVEBIS Hospital Study Team
dc.date.accessioned2024-02-14T11:25:10Z
dc.date.available2024-02-14T11:25:10Z
dc.date.issued2023-11
dc.descriptionMembers of the I-MOVE-COVID-19 and VEBIS hospital study teams (in addition to the named authors): Svjetlana Karabuva, Petra Tomaš Petrić, Marija Marković, Sandra Ljubičić, Bojana Mahmutović, Irena Tabain, Petra Smoljo, Iva Pem Novosel, Tanya Melillo, John Paul Cauchi, Benédicte Lissoir, Xavier Holemans, Marc Hainaut, Nicolas Dauby, Benedicte Delaere, Marc Bourgeois, Evelyn Petit, Marijke Reynders, Door Jouck, Koen Magerman, Marieke Bleyen, Melissa Vermeulen, Sébastien Fierens, François Dufrasne, Siel Daelemans, Ala’a Al Kerwi, Francoise Berthet, Guy Fagherazzi, Myriam Alexandre, Charlene Bennett, Jim Christle, Jeff Connell, Peter Doran, Laura Feeney, Binita Maharjan, Sinead McDermott, Rosa McNamara, Nadra Nurdin, Salif Mamadou Cissé, Anne-Sophie L'Honneur, Xavier Duval, Yolande Costa, Fidouh Nadhira, Florence Galtier, Laura Crantelle, Vincent Foulongne, Phillipe Vanhems, Sélilah Amour, Bruno Lina, Fabrice Lainé, Laetitia Gallais, Gisèle Lagathu, Anna Maisa, Yacine Saidi, Christine Durier, Rebecca Bauer, Ana Paula Rodrigues, Adriana Silva, Raquel Guiomar, Margarida Tavares, Débora Pereira, Maria José Manata, Heidi Gruner, André Almeida, Paula Pinto, Cristina Bárbara, Itziar Casado, Ana Miqueleiz, Ana Navascués, Camino Trobajo-Sanmartín, Miguel Fernández-Huerta, María Eugenia Portillo, Carmen Ezpeleta, Nerea Egüés, Manuel García Cenoz, Eva Ardanaz, Marcela Guevara, Conchi Moreno-Iribas, Hana Orlíková, Carmen Mihaela Dorobat, Carmen Manciuc, Simin Aysel Florescu, Alexandru Marin, Sorin Dinu, Catalina Pascu, Alina Ivanciuc, Iulia Bistriceanu, Mihaela Oprea, Maria Elena Mihai, Silke Buda, Ute Preuss, Marianne Wedde, Auksė Mickienė, Giedrė Gefenaitė, Alain Moren, Anthony Nardonept_PT
dc.description.abstractIntroduction: Two large multicentre European hospital networks have estimated vaccine effectiveness (VE) against COVID-19 since 2021. Aim: We aimed to measure VE against PCR-confirmed SARS-CoV-2 in hospitalised severe acute respiratory illness (SARI) patients ≥ 20 years, combining data from these networks during Alpha (March–June)- and Delta (June–December)-dominant periods, 2021. Methods: Forty-six participating hospitals across 14 countries follow a similar generic protocol using the test-negative case–control design. We defined complete primary series vaccination (PSV) as two doses of a two-dose or one of a single-dose vaccine ≥ 14 days before onset. Results: We included 1,087 cases (538 controls) and 1,669 cases (1,442 controls) in the Alpha- and Delta-dominant periods, respectively. During the Alpha period, VE against hospitalisation with SARS-CoV2 for complete Comirnaty PSV was 85% (95% CI: 69–92) overall and 75% (95% CI: 42–90) in those aged ≥ 80 years. During the Delta period, among SARI patients ≥ 20 years with symptom onset ≥ 150 days from last PSV dose, VE for complete Comirnaty PSV was 54% (95% CI: 18–74). Among those receiving Comirnaty PSV and mRNA booster (any product) ≥ 150 days after last PSV dose, VE was 91% (95% CI: 57–98). In time-since-vaccination analysis, complete all-product PSV VE was > 90% in those with their last dose < 90 days before onset; ≥ 70% in those 90–179 days before onset. Conclusions: Our results from this EU multi-country hospital setting showed that VE for complete PSV alone was higher in the Alpha- than the Delta-dominant period, and addition of a first booster dose during the latter period increased VE to over 90%.pt_PT
dc.description.abstractKey public health message: - What did you want to address in this study? To understand how well the COVID-19 vaccine was performing in Europe against hospitalisation during SARS-CoV-2 Alpha and Delta variant periods, we present vaccine effectiveness results from a multi-country study of complete and booster dose COVID-19 vaccination among adults (aged 20 years and over). - What have we learnt from this study? Between March and June 2021 (Alpha period), vaccine effectiveness against hospitalisation with laboratory-confirmed SARS-CoV-2 was 43% for partial vaccination and 86% for complete vaccination. For June to December 2021 (Delta period), vaccine effectiveness for complete vaccination was lower (52%) but with addition of an mRNA booster dose, effectiveness reached 91%, and remained > 90% up to 119 days after the booster dose. - What are the implications of your findings for public health? In Europe in 2021, COVID-19 vaccine effectiveness results for the Alpha period indicated an excellent benefit for preventing hospitalisation after complete vaccination. During Delta variant circulation, however, a booster dose was required to achieve this level of effectiveness, and this was maintained for up to 4 months post booster.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationEuro Surveill. 2023 Nov;28(47):2300186. doi: 10.2807/1560-7917.ES.2023.28.47.2300186pt_PT
dc.identifier.doi10.2807/1560-7917.ES.2023.28.47.2300186pt_PT
dc.identifier.issn1560-7917
dc.identifier.urihttp://hdl.handle.net/10400.18/9106
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherEuropean Centre for Disease Prevention and Controlpt_PT
dc.relationMultidisciplinary European network for research, prevention and control of the COVID-19 Pandemic
dc.relation.publisherversionhttps://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2023.28.47.2300186pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectCOVID-19pt_PT
dc.subjectSARS-CoV-2pt_PT
dc.subjectAlphapt_PT
dc.subjectDeltapt_PT
dc.subjectVaccine Effectivenesspt_PT
dc.subjectHospitalisationpt_PT
dc.subjectEuropept_PT
dc.subjectVacinapt_PT
dc.subjectEfetividadept_PT
dc.subjectIMOVE-COVID19pt_PT
dc.subjectCuidados de Saúdept_PT
dc.titleVaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021pt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.awardTitleMultidisciplinary European network for research, prevention and control of the COVID-19 Pandemic
oaire.awardURIinfo:eu-repo/grantAgreement/EC/H2020/101003673/EU
oaire.citation.issue47pt_PT
oaire.citation.startPage2300186pt_PT
oaire.citation.titleEurosurveillancept_PT
oaire.citation.volume28pt_PT
oaire.fundingStreamH2020
person.familyNameMachado
person.familyNameKislaya
person.familyNameGOMEZ TEIXEIRA PINTO
person.givenNameAusenda
person.givenNameIrina
person.givenNameVERÓNICA DEL PILAR
person.identifier.ciencia-id1217-6076-5D88
person.identifier.ciencia-idA815-4295-F91D
person.identifier.ciencia-idFA1B-D68F-2611
person.identifier.orcid0000-0002-1849-1499
person.identifier.orcid0000-0001-5772-2416
person.identifier.orcid0000-0003-0485-0005
person.identifier.scopus-author-id56442728800
project.funder.identifierhttp://doi.org/10.13039/501100008530
project.funder.nameEuropean Commission
rcaap.embargofctAcesso de acordo com política editorial da revista.pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication544ad266-0c22-4a50-9ebc-86acc08d6666
relation.isAuthorOfPublicationcf6a6914-1de2-4c2a-96b1-9d617ca28a15
relation.isAuthorOfPublicationeae04cda-2c73-437b-8666-6593d03aa34d
relation.isAuthorOfPublication.latestForDiscoveryeae04cda-2c73-437b-8666-6593d03aa34d
relation.isProjectOfPublication7403e02d-5360-418c-8e37-687c3a1349f8
relation.isProjectOfPublication.latestForDiscovery7403e02d-5360-418c-8e37-687c3a1349f8

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Vaccine effectiveness against COVID-19 hospitalisation in adults.pdf
Size:
771.18 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

DEP - Artigos em revistas internacionais